Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preventing problems in Ecstasy users: reduce use to reduce harm.

Matthew J Baggott1

  • 1matt@baggott.net

Journal of Psychoactive Drugs
|April 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of the MDMA-Assisted Psychotherapy Side Effects Tool (M-SET): a Delphi study.

BMJ open·2026
Same author

A repeated low-dose regimen of MDMA has transient next-day effects on locomotor activity, anxiety-like behavior, and brain serotonin levels, with no effect on anhedonia-like behavior, in both female and male rats.

Psychopharmacology·2026
Same author

Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine.

The Journal of pharmacology and experimental therapeutics·2024
Same author

Detection of acute 3,4-methylenedioxymethamphetamine (MDMA) effects across protocols using automated natural language processing.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2020
Same author

Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers.

Journal of psychoactive drugs·2019
Same author

The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?

Journal of psychopharmacology (Oxford, England)·2016
Same journal

Mystical Experiences as Catalysts in Ketamine-Assisted Psychotherapy: A Case Study.

Journal of psychoactive drugs·2026
Same journal

Cannabis-Induced Persistent Perceptual Disturbances: A Clinical Characterization Study of Multimodal Sensory Symptoms in 13 Patients.

Journal of psychoactive drugs·2026
Same journal

Specialist Inpatient Detoxification from Gabapentinoids: Clinical and Demographic Characteristics and Predictors of Outcome.

Journal of psychoactive drugs·2026
Same journal

Urine Prevalence of Psychoactive Substances, Nicotine Exposure and Associated Factors Among Commercial Drivers. An Exploratory Study.

Journal of psychoactive drugs·2026
Same journal

Latent Clusters of Peer Behaviors in Childhood and Relevance for Understanding Substance Use in Early Adolescence.

Journal of psychoactive drugs·2026
Same journal

Psychedelic Use, Microdosing, Motives, and Information and Product Sources Among Young Adults in the United States.

Journal of psychoactive drugs·2026
See all related articles

3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") use poses risks of neurotoxicity and common adverse effects. Prevention programs can leverage user-reported issues to encourage reduced Ecstasy consumption.

Area of Science:

  • Neuroscience
  • Toxicology
  • Public Health

Background:

  • Rising 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") usage prompts concerns regarding acute and long-term toxicity.
  • Existing research indicates potential neurophysiological and neurocognitive alterations in chronic Ecstasy users.

Purpose of the Study:

  • To review acute and chronic toxicity associated with Ecstasy use.
  • To explore implications for prevention and harm reduction strategies targeting Ecstasy users.

Main Methods:

  • Literature review and synthesis of existing research on Ecstasy toxicity.
  • Analysis of documented adverse events and user-reported problems.

Main Results:

  • Serious adverse events from Ecstasy are rare, complicating harm reduction efforts.

Related Experiment Videos

  • Chronic Ecstasy use shows evidence of neurophysiological changes and suggestive neurocognitive effects.
  • Common Ecstasy-related complaints, including acute and subacute effects, are well-documented with identifiable risk factors.

    • Conclusions:

    • Clinically subtle neurotoxic effects may not deter users, necessitating alternative prevention approaches.
    • Commonly experienced adverse effects and life problems associated with Ecstasy use can be leveraged for prevention.
    • Harm reduction programs can utilize user-reported issues to encourage reduced Ecstasy consumption and associated risks.